Skip to main content
Equibles

BDMD · Baird Medical Investment Holdings Ltd

Track BDMD — free

Use BDMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BDMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.10 -0.01 (-6.99%)
Rebalance outlook locked
Market Cap
$3.45M
Shares
32.11M
Volume · Nov 12 101.84M Avg daily vol (3M) 15.19M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.11 Open$0.10 Day$0.09–0.11 52W close$0.09–3.44 Avg vol 30d32.9M Short int218K · 0.7% of shares · 1.0d Short vol47% DataDec 2021–Nov 2026

Latest documents

2026
Nov 5
Current report 6-K
Minimum bid-price deficiency leaves listing status unchanged

Baird Medical Investment Holdings Limited received Nasdaq’s November 2, 2026 notice of a minimum bid-price deficiency; its shares continue trading under “BDMD.” It has 180 calendar days, until May 3, 2027, to regain compliance, with a possible additional 180-day grace period.

4 source passages
NEW YORK, November 4, 2026 – Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026 notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company’s shares, and Baird Medical’s shares will continue to trade, uninterrupted, on the Nasdaq Capital Market under the ticker “BDMD”. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until Monday, May 3, 2027, to regain compliance with the minimum bid price rule. In the event the Company does not regain compliance with the minimum bid price requirement by Monday, May 3, 2027, the Company may be eligible for an additional 180 calendar day grace period to regain compliance, or may face delisting. Open the document at this passage
Sep 30
Current report 6-K
Current report

Baird Medical Investment Holdings Limited agreed on September 24, 2026 to sell a senior 8% original issue discount convertible note in the principal amount of US$4,347,826, convertible into shares, and issue 110,070 discount shares for an additional 2% original issue discount.

Read from the first part of this long document
Sep 30
Current report 6-K
Current report

Baird Medical Investment Holdings Limited reported revenue of $9,915,407 and net income attributable to shareholders of $35,405 for the six months ended June 30, 2026, versus revenue of $7,959,494 and a net loss of $11,293,895 for 2025.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$24.49M
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-39.2%
Year over year
Operating margin
-58.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+27.3%
Year over year · more shares
Price change (1Y)
-91.6%
Trailing year
Short interest
0.7%
Latest settlement · 1.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Poor Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −92%
below
Price vs 50-day avg −83%
below
RSI (14) 23
oversold
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −82%
trailing
6-month return −93%
trailing
YTD return −92%
this year
Relative strength −95%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
12 of 39 funds reported for Sep 30 · net -37.6K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.68% of shares out · ▲ +858.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
39 holders — mid 1-yr range
Squeeze score 45
elevated · 0–100
Fundamentals
Poor
Revenue growth −39%
Y/Y
Gross margin 84%
contracting
EPS growth −272%
Y/Y
Free cash flow $-1.4M
Balance sheet $8.5M
net debt
Quant / Vol
risk profile
Very High
Volatility 148%
annualized · 1-yr
Max drawdown −97%
past year
ATR 71.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−92% Bearish
Price vs 50-day avg
−83% Bearish
RSI (14)
23 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
12 of 39 funds reported for Sep 30 · net -37.6K sh shares · +1 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
0.68% of shares out · ▲ +858.6% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
39 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $3
vs 200-day avg -92% vs 50-day avg -83%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BDMD
Baird Medical Investment Holdings Ltd
this stock
$3.45M -92.1% -39.2% — 0.0%
ABT
Abbott Laboratories
 $185.75B -14.4% +5.7% 40.0 1.1%
MDT
Medtronic plc
 $129.18B +5.1% +8.4% 24.9 1.8%
SYK
Stryker Corp
 $118.92B -11.1% +11.2% 33.3 1.7%
BSX
Boston Scientific Corp
 $64.07B -53.6% +12.5% 18.7 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
40
% held
19.7%
Reported
12 of 39
Top holder
Clear Street Group Inc.
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
217.6K
Days to cover
1.0d
Change
+194.9K sh
View
Short Volume
Short vol %
47%
As of
Nov 12, 2026
Short Total
View
Fails to Deliver
FTD shares
300
Value
$225
As of
Oct 13, 2026
View
Off-Exchange
Off-exchange %
52.1%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$22.5M
Net income (FY)
$-27.3M
EPS diluted
$-0.98
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 5, 2026
This year
9

Baird Medical Investment Holdings Limited received Nasdaq’s November 2, 2026 notice of a minimum bid-price deficiency; its shares continue trading under “BDMD.” It has 180 calendar days, until May 3, 2027, to regain compliance, with a possible additional 180-day grace period.

View

Performance

5D 20D 120D MTD YTD
BDMD -31.9% -82.1% -93.4% -33.1% -92.1%
SPY +3.3% -1.9% +1.5% +0.2% +11.0%
vs SPY -35.2% -80.2% -95.0% -33.3% -103.1%
Key facts CIK 1982444 CUSIP G0705H103 13F (30d) 7 filings 7 filers Visit website Investor relations